van Liessum P A, Swinkels L M, Pieters G F, Ross A A, Smals A G, Benraad T J, Kloppenborg P W
Department of Medicine, University Hospital, University of Nijinegen, The Netherlands.
Acta Endocrinol (Copenh). 1990 Mar;122(3):309-12. doi: 10.1530/acta.0.1220309.
Serum samples from 13 patients with active acromegaly on long-term sc treatment with octreotide (SMS 201-995, 1-36 months, mean daily dose 285 micrograms) were taken 12 h after the injection of their regular evening doses. Octreotide assay was performed using 125I-Tyr-SMS and a polyclonal rabbit anti-serum. For assessment of antibody formation both serum coated charcoal adsorption (adsorption of free octreotide) and polyethylene glycol precipitation (precipitation of IgG complexes) were used. The mean binding percentage in the patients proved to be similar to that of 5 healthy volunteers (p greater than 0.10). No specific binding was detected, whatever method used. No correlation was found between the binding percentages and octreotide serum levels, duration of octreotide treatment or daily octreotide dose (p greater than 0.10). These results strongly suggest that clinically relevant endogenous antibody formation is not a frequent event during long-term sc treatment of acromegalic patients with octreotide.
选取13例接受长效奥曲肽皮下注射治疗（使用SMS 201-995，治疗1至36个月，平均日剂量285微克）的活动性肢端肥大症患者，于其常规晚间剂量注射12小时后采集血清样本。采用125I-Tyr-SMS和兔多克隆抗血清进行奥曲肽检测。为评估抗体形成情况，同时使用了血清包被活性炭吸附法（游离奥曲肽的吸附）和聚乙二醇沉淀法（IgG复合物的沉淀）。结果显示，患者的平均结合百分比与5名健康志愿者的相似（p＞0.10）。无论采用何种方法，均未检测到特异性结合。结合百分比与奥曲肽血清水平、奥曲肽治疗时长或奥曲肽日剂量之间均未发现相关性（p＞0.10）。这些结果有力地表明，在肢端肥大症患者长期皮下注射奥曲肽治疗过程中，临床上相关的内源性抗体形成并非常见事件。
